A Study to Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of JNJ-404118413 in Healthy Male Patients

NCT01951053 ↗

Phase 1 Completed 18 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

RandomizedCrossoverQuadruple-blind

Summary

The purpose of the study is to evaluate the effect of JNJ-40411813 on rapid eye movement sleep and deep sleep; safety, tolerability and pharmacokinetics (what the body does to the study medication) of JNJ-40411813.

Timeline

Start: 2010-01
Primary completion: 2010-05
Completion: 2010-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Citalopram	Small molecule	20 mg	Oral
Subject	JNJ-40411813	Small molecule	500 mg	Oral

Indications

No indication recorded.